1. Belgium Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Oxurion NV

Oxurion NV

0.00
EUR
0.00
(0.00%)
919,360.22Market Cap
Mar 03Next Earn
Oxurion NV
GETTEX:TG40
(Gettex)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
2,101.77
754.4
21,489.27
31,310.66
3,817.12
3,102.8
1,968.41
2,509.01
1,390.85
1,030.56
542.7
293.67
69.99
1.59
- -
0.02
- -
Revenue per Share
-4,745.41
-6,676.03
8,702.43
7,329.54
-14,163.2
-10,497.09
-16,712.11
6,314.21
-10,058.56
-13,535.39
-7,315.75
-7,591.25
-3,727.21
-114.82
0.09
-0.13
- -
Basic EPS, GAAP
-8,715.11
-9,792.04
-2,692.7
5,608.27
-13,067.89
-7,799.11
-6,062.9
7,217.79
-8,185.88
-8,245.49
-7,103.16
-7,032.02
-2,286.55
-59.11
-1.63
-0.06
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
42,677.58
36,383.79
63,571.11
71,701.86
57,637.02
47,087.28
30,428.37
36,749.79
27,393.05
13,883.52
6,576.13
-275.99
-111.49
-37.79
-3.46
-0.21
-3.46
Book Value per Share
33,901.17
24,174.48
42,677.64
51,808.53
39,633.69
30,937.38
23,251.32
30,209.75
22,052.23
13,365.89
6,020.63
-532
-111.49
-37.79
-3.46
-0.22
-3.46
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
28
1
Basic Weighted Avg Shares
6
2
75
113
14
11
7
9
5
4
2
1
1
- -
- -
1
- -
Sales/Revenue/Turnover
-237.41
-1,014.44
38.75
22.62
-382.65
-347.54
-482.09
256.94
-737.61
-894.15
-1,371.27
-2,426.24
-3,688.4
-4,555.89
12,733.33
-590.81
- -
Operating Margin (%)
- -
- -
1
8
8
8
34
4
4
20
1
2
1
- -
- -
- -
- -
Depreciation Expense
-14
-22
30
26
-51
-38
-60
23
-38
-52
-28
-29
-32
-19
- -
-4
- -
Net Income, GAAP
- -
- -
0.11
0.05
- -
- -
- -
0.06
- -
- -
- -
- -
- -
- -
2.46
- -
- -
Effective Tax Rate (%)
-225.78
-884.95
40.5
23.41
-371.04
-338.31
-849.01
251.66
-723.2
-1,313.41
-1,348.03
-2,584.93
-5,325.21
-7,212.55
3,966.67
-671.71
- -
Profit Margin (%)
109
77
145
179
136
108
80
107
82
47
19
2
-5
-17
-13
-14
-13
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
8
4
- -
- -
- -
- -
LT Debt
138
118
228
259
208
170
110
133
105
53
25
-1
-5
-13
-11
-13
-11
Total Equity
- -
- -
16.8
10.48
- -
- -
- -
19.12
- -
- -
- -
- -
- -
- -
-127.82
- -
- -
Return on Invested Capital (%)
- -
- -
17.6
10.86
- -
- -
- -
18.91
- -
- -
- -
- -
- -
- -
-45.51
- -
- -
Return on Capital (%)
-12.02
-16.89
17.58
10.85
-21.9
-20.05
-43.12
18.8
-32.4
-65.58
-71.51
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
12
12
11
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
1
3
Market Capitalization
- -
- -
1

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
3
2
4
Cash, Cash Equivalents & STI
2
- -
- -
Accounts Receivable, Net
- -
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
20
19
17
Payables & Accruals
- -
- -
- -
ST Debt
12
12
11
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.81%
79.11%
14.75%
Free Cash Flow
-64.94%
-34.97%
-17.55%
Net Income, GAAP
-371.94%
-672.15%
-3,232.77%
Sales/Revenue/Turnover
1,802.88%
3,630.47%
18,400%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
1

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-114.82
2024
- -
- -
0.09
2025
- -
- -
-0.13

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical company focused on developing next-generation therapies to preserve vision in patients with retinal disorders, including geographic atrophy and age-related macular degeneration; it employs a CRISPR-based target discovery platform to identify cytoprotective targets beyond traditional complement pathways, advancing preclinical programs toward multi-specific lead candidates for geographic atrophy. The company offers innovative treatments addressing unmet needs in ophthalmology, with expertise spanning retinal diseases such as wet and dry AMD, diabetic macular edema, and vitreomacular adhesion; it previously commercialized Jetrea (ocriplasmin), the only approved pharmacological vitreolysis drug, licensed worldwide to Inceptua Group through 2023. Founded in 1991 as ThromboGenics NV and renamed Oxurion NV in 2018, Oxurion maintains headquarters in Leuven, Belgium, with wholly owned subsidiaries ThromboGenics Inc. in New York, USA, Oncurious NV and Oxurion France SAS in Leuven and Toulouse respectively; operations center on R&D at its GMP-certified Bio-Incubator facility in Leuven, targeting markets in Europe and North America through a strategy blending internal innovation with healthcare sector acquisitions. Recent strategic shifts include a comprehensive restructuring in partnership with Atlas Special Opportunities LLC, securing committed but conditional funding up to 20 million euro via convertible bonds to support operations through 2025 amid share consolidation in September 2024; in August 2025, Oxurion acquired 72% of Axiodis CRO, a French biometrics and clinical data management specialist with proprietary eCRF platform, financed by Atlas and aligning with ambitions to build an integrated clinical trial platform as a one-stop shop for clients from trial design to market access. In October 2025, Oxurion signed a letter of intent for an additional CRO acquisition emphasizing clinical operations, regulatory affairs, medical affairs, scientific communication, and market access, with exclusivity through December 31, 2025 and ongoing due diligence to create synergies with Axiodis; discussions on a prior preclinical target ended in November 2025 to prioritize financial discipline and high-value clinical integration, reinforcing focus on revenue-generating European subcontractors in clinical development.